SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Acquisition, CDC Contract Win and Trading Update

7 Jul 2016 07:00

RNS Number : 4823D
Rentokil Initial PLC
07 July 2016
 

 

7 July 2016

Acquisition, CDC Contract Win and Trading Update

Rentokil acquires Residex

Rentokil Initial plc (FTSE: RTO, "the Company") announces its continued expansion in North America with the acquisition of pest control and turf products distribution business Residex LLC ("Residex") for US$30m.

Residex is the largest independent products distribution company in the US, with annualised revenues for the 12 months prior to acquisition of $113m. The acquisition increases the scale of the Company's existing pest and turf products business, which more than doubles in size. It creates the second largest business of this type in the US market, delivering national coverage and a greater density footprint.

Andy Ransom, Chief Executive of Rentokil Initial plc, said: "I'm delighted to welcome the Residex team to Rentokil Initial. North America is a strategic growth market for Rentokil with great potential for continued profitable growth and our acquisition pipeline remains strong. The addition of Residex means that our business in North America is set to deliver annualised revenues of around $1 billion by the end of the year - some two years ahead of our expectations."

In the first half of 2016 the Company completed a series of 20 highly-targeted city-based acquisitions, predominantly in Pest Control in North America, Asia, Pacific and Europe. Total annualised revenues in the year prior to acquisition for these businesses acquired, including Residex, were c. £100m.

Rentokil wins two-year contract with the US government to combat Zika virus

Rentokil North America has been awarded a contract by the U.S. Centers for Disease Control and Prevention ("CDC") to help control the species of mosquito that could potentially carry the Zika virus across the USA and its protectorates. The requirement of the programme is to provide pest control services until June 2018, subject to government review. As required, Rentokil will deploy its network of more than 4,000 pest control experts alongside its global technical resource to target affected or high-risk areas. Additionally, a key component of the contract includes support services that entail community outreach, surveillance and inspection, and support for the distribution of materials and educational information.

Andy Ransom, Chief Executive of Rentokil Initial plc, said: "I'm proud that Rentokil has been selected to support the work of the CDC throughout the USA. Across the world we combat the dangers to public health from mosquitoes such as Dengue fever in Asia, to Malaria and West Nile virus in Africa and the Americas. Our depth of expertise and experience in global mosquito control is simply unmatched."

Trading update

Following its First Quarter trading announcement on 20 April the Company has continued to perform well and our expectations for 2016 at constant exchange rates remain unchanged.

In respect of the outcome of the EU Referendum and the UK's decision to leave the EU, we advise that approximately 90% of the Company's revenues are derived from outside the UK and there is minimal cross-border trading across its global businesses. Sterling has weakened significantly since the announcement and, if recent rates were to prevail for the remainder of the year, the estimated favourable impact of currency movements on our profit for 2016 would be in the range of £25m to £30m. This would be an increase of £10m to £15m on the guidance previously given at the time of our Preliminary results.

We also note that on 29 June 2016, Standard & Poor's removed its negative outlook from the Company's BBB debt rating, reflecting continued good progress in the execution of the Steritech integration.

 

The Company will provide more details on its H1 performance and its prospects for the remainder of 2016 at its Interim Results on 28 July 2016.

 

Notes to Editors

 

About Rentokil Initial plc

Rentokil Initial is one of the largest business services companies in the world, operating in over 60 countries. The Company offers route-based services including Pest Control, Hygiene and Workwear through teams of local experts.

 

About Products Distribution

 

The Company's existing Target Specialty Products business is a leading US national wholesale distributor of specialty agricultural chemicals, application equipment, products, supplies, services and education. It provides products and services to both private and public sector industries including structural pest control, landscape construction and maintenance, golf course maintenance and turfgrass maintenance, production nursery, industrial vegetation management, aquatic, forestry and vector control.

 

Residex LLC is a Michigan headquartered pest products and turf management products distribution company. It was founded in 1946 and in 2010 it merged with Turfgrass, adding turf products to Residex's predominantly pest products business. Today the company's sales are approximately 50 per cent pest products and 50 per cent turf products. It sells its products throughout the US and Canada with a particular focus on the Midwest, South East and North East US.

 

 

Enquiries:

 

Investor / Analyst enquiries: Katharine Rycroft, Investor Relations, Rentokil Initial plc: 07811 270 734

Media enquiries: Malcolm Padley, Corporate Communications, Rentokil Initial plc: 07788 978 199 Ben Woodford / Sam Cartwright, Bell Pottinger: 0203 772 2566

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQUGUBUMUPQPGQ
Date   Source Headline
21st May 20267:00 amRNSAppointment of CEO, North America
8th May 202610:30 amRNSHolding(s) in Company
7th May 20264:40 pmRNSResult of AGM
23rd Apr 20264:25 pmRNSFinal Dividend – Pence Sterling Amount Payable
23rd Apr 20262:30 pmRNSIssuance of $500 million 4.625% Notes due 2031
21st Apr 202610:30 amRNSHolding(s) in Company
16th Apr 20267:00 amRNSQ1 Trading Update
15th Apr 20267:00 amRNSDirectorate Change
30th Mar 202610:30 amRNSHolding(s) in Company
26th Mar 20263:46 pmRNSDirector/PDMR Shareholding
25th Mar 202610:50 amRNSAnnual Financial Report
17th Mar 20264:30 pmRNSDirector/PDMR Shareholding
16th Mar 202610:32 amRNSHolding(s) in Company
16th Mar 202610:32 amRNSHolding(s) in Company
12th Mar 202610:30 amRNSHolding(s) in Company
10th Mar 20264:28 pmRNSDirector/PDMR Shareholding
10th Mar 20264:28 pmRNSDirector/PDMR Shareholding
10th Mar 20264:26 pmRNSDirector/PDMR Shareholding
10th Mar 20264:26 pmRNSDirector/PDMR Shareholding
9th Mar 202611:15 amRNSHolding(s) in Company
5th Mar 20267:00 amRNSPreliminary Results
5th Mar 20267:00 amRNSChair Succession Planning Update
23rd Feb 202610:30 amRNSHolding(s) in Company
19th Feb 20262:50 pmRNSDirector Declaration
12th Feb 20265:30 pmRNSNotice of Early Redemption
20th Jan 202610:25 amRNSHolding(s) in Company
19th Jan 202610:30 amRNSHolding(s) in Company
16th Jan 20263:00 pmRNSHolding(s) in Company
14th Jan 202610:30 amRNSHolding(s) in Company
13th Jan 202610:30 amRNSHolding(s) in Company
13th Jan 20267:00 amRNSDirectorate change
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
19th Dec 202511:00 amRNSDirector/PDMR Shareholding
5th Dec 202510:30 amRNSHolding(s) in Company
5th Dec 202510:30 amRNSHolding(s) in Company
26th Nov 20254:25 pmRNSHolding(s) in Company
28th Oct 202510:45 amRNSHolding(s) in Company
28th Oct 202510:45 amRNSHolding(s) in Company
27th Oct 202510:30 amRNSHolding(s) in Company
23rd Oct 202511:45 amRNSHolding(s) in Company
23rd Oct 20257:00 amRNSQ3 Trading Update
21st Oct 202510:00 amRNSHolding(s) in Company
14th Oct 202510:00 amRNSHolding(s) in Company
1st Oct 202510:30 amRNSBlock listing Interim Review
30th Sep 202510:30 amRNSCompletion of France Workwear business sale
25th Sep 20254:15 pmRNSDirector/PDMR Shareholding
24th Sep 20256:00 pmRNSDirector Declaration
26th Aug 202512:30 pmRNSInterim Dividend – Pence Sterling Amount Payable
7th Aug 202511:10 amRNSHolding(s) in Company
31st Jul 20257:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.